FDA accelerated approval covers zanidatamab-hrii for HER2-positive biliary tract cancerNov 12Regulatory decisionJazz Pharmaceuticalszanidatamab-hrii
Zymeworks raises 2026 guidance after $250M Ziihera milestone, posts Roche deal for ZW209Nov 9Quarterly updateJazz PharmaceuticalsRoche
Jazz Pharmaceuticals' Phase I ONC206 trial in CNS neoplasms updated, remains active not recruitingNov 9Trial updateJazz PharmaceuticalsJZP3507
Jazz posts Phase 2 results for zanidatamab combo in GI cancers; JZP269 trial recruitsNov 4Weekly roundup, 2 itemsJazz PharmaceuticalsJZP269
Jazz Pharmaceuticals posts record quarterly revenue, raises 2026 guidanceNov 2Quarterly updateJazz Pharmaceuticalszanidatamab-hrii
MD Anderson registers Phase 1a/1b trial combining Jazz's zanidatamab with Boehringer's zongertinib iOct 28Trial updateBoehringer IngelheimJazz Pharmaceuticals
Jazz Pharmaceuticals flags ~$755 million IPR&D charge tied to Actio Biosciences dealOct 26Quarterly updateJazz Pharmaceuticals
St. Jude posts results for CPX-351 pilot study in pediatric secondary myeloid neoplasmsOct 15Trial update(daunorubicin and cytarabine) liposomeJazz Pharmaceuticals
Jazz Pharmaceuticals discloses retirement plan for chief commercial officerOct 9PeopleJazz Pharmaceuticals
Jazz Pharmaceuticals registers Phase 2/3 trial of JZP926 for juvenile myoclonic epilepsyOct 6Trial updatecannabidiolJazz Pharmaceuticals
University of Washington trial of Rylaze in adult ALL remains suspended for safety reviewOct 5Clinical readoutasparaginase erwinia chrysanthemi (recombinant)-rywnGenmab A/SUpdated
FDA approves labeling supplement for Jazz's Zepzelca (lurbinectedin)Sep 30Regulatory decisionJazz Pharmaceuticalslurbinectedin
Jazz-linked lurbinectedin GI trial posts results; new JZP269 Phase 1 study registeredSep 11Weekly roundup, 2 itemsJazz PharmaceuticalsJZP269
Jazz Pharmaceuticals closes $1.25 billion exchangeable notes offeringAug 31FinancingJazz Pharmaceuticals
Roswell Park's Phase II CPX-351 trial in younger secondary AML patients marked completedAug 31Trial updateJazz Pharmaceuticals
Jazz posts results for XYWAV sleep study; registers new zanidatamab real-world studyAug 27Weekly roundup, 2 itemsJazz PharmaceuticalsXywav
FDA approves Ziihera in two regimens for first-line HER2+ gastroesophageal cancerAug 25Regulatory decisionJazz Pharmaceuticalszanidatamab-hrii
FDA approves Ziihera-based regimens for first-line HER2+ gastroesophageal cancerAug 25Regulatory decisionBeiGeneJazz Pharmaceuticals